MX2018014425A - Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. - Google Patents
Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.Info
- Publication number
- MX2018014425A MX2018014425A MX2018014425A MX2018014425A MX2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A
- Authority
- MX
- Mexico
- Prior art keywords
- pro
- diseases
- neutrophil elastase
- human neutrophil
- inhibitory activity
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 2
- 239000000816 peptidomimetic Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 230000002849 elastaseinhibitory effect Effects 0.000 title 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 3
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 3
- 102000052502 human ELANE Human genes 0.000 abstract 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a aerosoles farmacéuticos que comprenden una ß-horquilla peptidomimética de fórmula ciclo (-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), o una sal farmacéuticamente aceptable del mismo, que tiene actividad inhibidora contra elastasa de neutrófilo humana. Además, se refiere a composiciones farmacéuticas sólidas o líquidas y kits para preparar y administrar tales aerosoles. La invención se puede utilizar para la prevención, manejo o tratamiento de enfermedades pulmonares, tal como la deficiencia de antitripsina alfa-1 (AATD), fibrosis quística (CF), bronquiactasia fibrosa no quística (NCFB) o enfermedad pulmonar obstructiva crónica (COPD), o infecciones, o enfermedades o afecciones de los pulmones, que son mediadas o que resultan de la actividad de la elastasa de neutrófilo humana. Por lo tanto, la invención se refiere además a una composición farmacéutica o un aerosol farmacéutico que comprende el compuesto activo ciclo (-OctG-Glu-Thr-Ala-Ser-Ile-Pro -Pro-Gln-Lys-Tyr-DPro-Pro-), o cualquier sal farmacéuticamente aceptable del mismo, para uso en un método para la prevención, manejo o tratamiento de enfermedades o afecciones de los pulmones que son mediadas o que resultan de la actividad de la elastasa de neutrófilo en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020210 | 2016-05-31 | ||
| PCT/EP2017/025156 WO2017207117A1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014425A true MX2018014425A (es) | 2019-03-28 |
Family
ID=56108445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014752A MX2018014752A (es) | 2016-05-31 | 2017-05-31 | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. |
| MX2018014425A MX2018014425A (es) | 2016-05-31 | 2017-05-31 | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014752A MX2018014752A (es) | 2016-05-31 | 2017-05-31 | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11235023B2 (es) |
| EP (2) | EP3463281B1 (es) |
| JP (4) | JP7286319B6 (es) |
| KR (2) | KR102511284B1 (es) |
| CN (3) | CN109310613A (es) |
| AU (2) | AU2017273508B2 (es) |
| BR (2) | BR112018074532B1 (es) |
| CA (2) | CA3024522A1 (es) |
| CL (2) | CL2018003391A1 (es) |
| DK (2) | DK3463281T3 (es) |
| EA (2) | EA039603B1 (es) |
| ES (2) | ES2928050T3 (es) |
| HR (2) | HRP20221185T1 (es) |
| HU (2) | HUE060393T2 (es) |
| IL (2) | IL263112B2 (es) |
| LT (2) | LT3463280T (es) |
| MA (2) | MA45168A (es) |
| MX (2) | MX2018014752A (es) |
| PH (2) | PH12018502522A1 (es) |
| PL (2) | PL3463281T3 (es) |
| PT (2) | PT3463281T (es) |
| RS (2) | RS63622B1 (es) |
| SG (3) | SG11201810137UA (es) |
| UA (2) | UA125899C2 (es) |
| WO (2) | WO2017207118A1 (es) |
| ZA (2) | ZA201807772B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE060393T2 (hu) * | 2016-05-31 | 2023-02-28 | Spexis Ag | Béta-hairpin peptidomimetikum elasztáz gátló hatással és annak aeroszolos adagolási formái |
| BR112022014861A2 (pt) * | 2020-01-30 | 2022-09-20 | Vertex Pharma | Métodos de tratamento para deficiência de alfa-1 antittripsina |
| MX2023005982A (es) * | 2020-11-23 | 2023-08-15 | Spexis Ag | Composiciones de un peptidomimetico de horquilla beta y formas de dosificacion en aerosol del mismo. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69718047T2 (de) * | 1996-11-01 | 2003-11-13 | Xoma Technology Ltd | Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose |
| AU2006206272A1 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
| KR101420198B1 (ko) * | 2005-02-17 | 2014-08-13 | 폴리포 리미티드 | 프로테아제 저해 활성을 가지는 주형-고정된 β-헤어핀 구조의 펩티드모방체 |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| DK1981572T3 (da) | 2006-02-09 | 2013-03-04 | Pari Pharma Gmbh | Pulmonal afgivelse af alfa-1-proteinaseinhibitor |
| LT1991201T (lt) * | 2006-02-10 | 2018-07-25 | Pari Pharma Gmbh | Puškiami antibiotikai inhaliaciniam gydymui |
| WO2008025560A1 (en) | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| ES2532667T3 (es) | 2011-09-12 | 2015-03-30 | Meiji Seika Pharma Co., Ltd. | Composiciones acuosas que contienen arbekacina |
| WO2015096672A1 (zh) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | 测试装置 |
| JP6431486B2 (ja) | 2013-12-26 | 2018-11-28 | 株式会社カネカ | 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール |
| SI3087094T1 (sl) * | 2013-12-27 | 2022-11-30 | Spexis Ag | BETA-lasnični peptidomimetiki kot selektivni zaviralci elastaze |
| EA034910B1 (ru) | 2013-12-27 | 2020-04-06 | Полифор Аг | Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы |
| HUE060393T2 (hu) * | 2016-05-31 | 2023-02-28 | Spexis Ag | Béta-hairpin peptidomimetikum elasztáz gátló hatással és annak aeroszolos adagolási formái |
-
2017
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/hu unknown
- 2017-05-31 ES ES17733738T patent/ES2928050T3/es active Active
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en unknown
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 CA CA3024522A patent/CA3024522A1/en active Pending
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/zh active Pending
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/pt active IP Right Grant
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/da active
- 2017-05-31 RS RS20220923A patent/RS63622B1/sr unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/hr unknown
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/lt unknown
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/pl unknown
- 2017-05-31 ES ES17733737T patent/ES2927948T3/es active Active
- 2017-05-31 MX MX2018014752A patent/MX2018014752A/es unknown
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/ko active IP Right Grant
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/hr unknown
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/pt active IP Right Grant
- 2017-05-31 RS RS20220922A patent/RS63639B1/sr unknown
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en active Active
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/lt unknown
- 2017-05-31 UA UAA201812929A patent/UA125899C2/uk unknown
- 2017-05-31 PT PT177337383T patent/PT3463281T/pt unknown
- 2017-05-31 MA MA045168A patent/MA45168A/fr unknown
- 2017-05-31 UA UAA201812930A patent/UA125900C2/uk unknown
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/zh active Pending
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/es unknown
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/ko active IP Right Grant
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/da active
- 2017-05-31 PT PT177337375T patent/PT3463280T/pt unknown
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en active Active
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/ja active Active
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/zh active Pending
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en unknown
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/pl unknown
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/hu unknown
- 2017-05-31 JP JP2018562549A patent/JP2019523222A/ja active Pending
- 2017-05-31 EA EA201892818A patent/EA039603B1/ru unknown
- 2017-05-31 EA EA201892819A patent/EA201892819A1/ru unknown
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 MA MA045167A patent/MA45167A/fr unknown
-
2018
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/es unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/es unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/ja active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501439B1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| NZ734516A (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| NZ708593A (en) | Novel pyrazole derivative | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| PH12018502522A1 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
| WO2012016889A3 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| WO2016109217A3 (en) | Btk inhibitors | |
| WO2013112959A8 (en) | Antifibrotic compounds and uses thereof | |
| WO2015187542A8 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| HRP20140707T1 (hr) | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| WO2014008248A3 (en) | Compositions and methods for treating and inhibiting viral infections | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
| WO2015048641A3 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
| WO2017178897A3 (en) | Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists | |
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
| WO2016013877A3 (en) | A novel compound isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the composition comprising the same for preventing or treating allergy disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof | |
| MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| EA201500486A1 (ru) | Фармацевтическая композиция для аэрозольного применения и ее получение |